228 related articles for article (PubMed ID: 26718275)
1. Vas Narasimhan.
Narasimhan V; Mullard A
Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275
[No Abstract] [Full Text] [Related]
2. 2011 in reflection.
Mullard A
Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
[No Abstract] [Full Text] [Related]
3. Novelty in the target landscape of the pharmaceutical industry.
Agarwal P; Sanseau P; Cardon LR
Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
[No Abstract] [Full Text] [Related]
4. Q&A: Bernard Munos.
Bender E
Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
[No Abstract] [Full Text] [Related]
5. Ian Tomlinson.
Tomlinson I
Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183
[No Abstract] [Full Text] [Related]
6. Trial watch: Clinical trial cycle times continue to increase despite industry efforts.
Martin L; Hutchens M; Hawkins C
Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041
[No Abstract] [Full Text] [Related]
7. Marc Kirschner. Interview by Asher Mullard.
Kirschner M
Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
[No Abstract] [Full Text] [Related]
8. Traditional drug-discovery model ripe for reform.
Cressey D
Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
[No Abstract] [Full Text] [Related]
9. To make better therapeutics, companies strive to increase the content of results and get them faster.
Szpir M
Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
[No Abstract] [Full Text] [Related]
10. Translational regenerative medicine research: essential to discovery and outcome.
Mason C; Dunnill P
Regen Med; 2007 May; 2(3):227-9. PubMed ID: 17511558
[No Abstract] [Full Text] [Related]
11. Trial watch: personalized medicines in late-stage development.
Milne CP; Garafalo S; Bryan C; McKiernan M
Nat Rev Drug Discov; 2014 May; 13(5):324-5. PubMed ID: 24781541
[No Abstract] [Full Text] [Related]
12. Virtual drug discovery with the rise of Chinese CROs.
Zhang MQ
Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343
[No Abstract] [Full Text] [Related]
13. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
14. Could pharma open its drug freezers?
Mullard A
Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
[No Abstract] [Full Text] [Related]
15. An audience with...John Reed.
Reed J; Mullard A
Nat Rev Drug Discov; 2014 Mar; 13(3):170-1. PubMed ID: 24577393
[No Abstract] [Full Text] [Related]
16. The role of discovery DMPK scientists in industry: where do we go from here?
Moriwaki T
Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
[No Abstract] [Full Text] [Related]
17. An audience with Patrick Vallance.
Vallance P
Nat Rev Drug Discov; 2010 Nov; 9(11):834. PubMed ID: 21030993
[No Abstract] [Full Text] [Related]
18. Menelas Pangalos. Interview by Asher Mullard.
Mullard A
Nat Rev Drug Discov; 2013 Jun; 12(6):418. PubMed ID: 23722338
[No Abstract] [Full Text] [Related]
19. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
Smith BJ
Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
[No Abstract] [Full Text] [Related]
20. Partnering for therapeutics discovery.
Colvis CM; Devaney S; Brady LS; Hudson KL
Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
